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ABSTRACT 
  Polymeric film-forming solutions (FFSs) are novel and emerging drug delivery 
systems for topical application to the skin. In their simplest composition, they constitute an 
active drug substance, film-forming polymer, and a volatile skin-tolerant solvent. When applied 
to the skin, FFSs form a thin and transparent polymeric film shortly after solvent evaporation. 
Owing to their unique composition and formation mechanism, these systems offer many superior 
advantages to the more conventional topical dosage forms. Thereby, this work aimed to develop 
and characterize film forming solutions for the skin delivery of two of the most commonly used 
topical non-steroidal anti-inflammatory drugs (NSAIDS); ketoprofen and diclofenac sodium.  
FFS were developed by varying the type and content of the film forming polymer. The 
resulting formulations were evaluated according to favorable film characteristics, in vitro and ex 
vivo drug release profiles. Eudragit E100 was identified as a suitable release matrix for 
ketoprofen. In the case of diclofenac Na; however, the ex vivo permeation study results failed to 
show a characteristic release profile for either the test formulation or the marketed formulation 
VOLTAREN® Gel.  
Nevertheless, the presented work provided a rationalized way for the development and 
evaluation of FFS and investigated their potential as delivery systems for ketoprofen and 
diclofenac sodium. 
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CHAPTER I 
INTRODUCTION 
In situ film forming polymeric solution is a novel and emerging approach for dermal and 
transdermal drug delivery. These solutions in their simplest composition comprise a drug 
substance, a film-forming polymer, and a skin-tolerant volatile solvent1. They are applied on the 
skin as liquids forming a very thin polymeric film after the rapid evaporation of the solvent. The 
formed films provide superior advantages over the more conventional topical dosage forms; they 
are flexible, fast-drying, less greasy and do not carry the risk of being wiped off the skin compared 
to semisolid formulations. Above all, the most crucial attribute of in situ film forming solutions is 
the complete skin contact over the entire application period without causing any skin fixation or 
irritation as in the case of topical patches. This potential advantage is especially essential for the 
management of chronic skin diseases where the repetitive application is a major cause of poor 
patient compliance and satisfaction as well as poor therapeutic outcomes.  
Based on this rational, two of the most prescribed topical non-steroidal anti-inflammatory 
drugs (NSAIDS); ketoprofen and diclofenac Na were formulated as polymeric film-forming 
solutions for skin delivery. Table 1 represents some of the physical and chemical properties of 
diclofenac Na and ketoprofen2,3.
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Table 1: Some of ketoprofen and diclofenac Na physical and chemical properties 
Property Ketoprofen Diclofenac Na 
Molecular weight 254.28 g/mol 296.14 g/mol 
Melting point 94° C 283° C 
Octanol/water partioning 
coefficient  
3.12 4.51 
Dissociation coefficient 4.45 4.15 
Aqueous solubility 51 mg/L 2.37 mg/L 
                              
Accordingly, the presented work aimed to develop FFS formulations of ketoprofen and 
diclofenac Na using different types and concentrations of film-forming polymers and to 
characterize and optimize the resulting formulations according to favorable film characteristics, 
in vitro and ex vivo drug release profiles. 
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CHAPTER II 
OBJECTIVE OF THE STUDY 
The objective of the present work was to develop, characterize and optimize FFSs for the 
topical delivery of ketoprofen and diclofenac Na.  
Research Strategy: The study was divided into two parts; the former was focused on the 
formulation of different polymeric FFS formulations by varying the type and content of the 
polymer. A selection of 13 polymers from different chemical groups, all described by their 
manufacturer or in the literature as being film formers, were tested and evaluated for their film 
characteristic and drug loading capacities. In the second part, we determined the in vitro, and ex 
vivo release profiles of the formulations that passed the first stage of testing. All formulations were 
made in two batches and were subjected to stability conditions for three months. Formulations 
were kept at two conditions, 25ᵒC/60% RH and 40ᵒC/75% RH respectively.  
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CHAPTER III 
MATERIALS AND METHODS 
Materials 
Ketoprofen was purchased from Tokyo Chemical Industry Co., Ltd. Diclofenac sodium 
salt, Chitosan and Poly( acrylic acid) were purchased from Sigma -Aldrich. Eudragit E100® 
(dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate), Eudragit 
EPO® (dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate), 
Eudragit RLPO® (Methacrylic acid methylacrylate copolymer), and Eudragit RS100® were 
purchased from Evonik Industries. Kollidon® 30 (Polyvinylpyrrolidone), Kollidon 90F®, 
Kollidon SR, Soluplus® ( polyethylene glycol, polyvinyl acetate, and polyvinylcaprolactame-
based graft copolymer) and Luterol® (Plyoxyl propylene-polyoxyethylene block copolymer) 
were purchased from BASF. Carbopol was purchased from Lubrizol Corporation. Menthol was 
purchased from Ward’s Natural Science. High-Performance Liquid Chromatography (HPLC)-
grade solvents like methanol, ethanol were purchased from Fisher Chemicals, USA. Porcine skin 
was obtained from Pontotoc Slaughterhouse, Pontotoc, MS, USA. Dermatomed human cadaver 
skin was purchased from New York Firefighters Skin Bank. 
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Methods 
Polymer screening 
A selection of 13 polymers from different chemical classes were evaluated for their 
solubility in 95% ethanol and the resulting film characteristics. The screened polymers herein 
were all described by their manufacturer or in the literature as being film formers. Table 2 
represents all the polymers that were used in this experiment. 
Table 2: Polymers used in the screening experiment 
Trade name Polymer 
Eudragit E 100 Poly(butyl methacrylate, (2-
dimethylaminoethyl)methacrylate, methyl 
methacrylate) 1:2:1 
Eudragit RLPO Ammonio methacrylate copolymer type A 
Eudragit EPO Butyl methylacrylate-(2-Dimethylaminoethyl) 
methacrylate-Methyl methacrylate-copolymer 
Kollidon 30 Polyvinylpyrrolidone 
 
Kollidon 90F Polyvinylpyrrolidone higher molecular weight 
 
Kollidon SR A blend of polyvinyl acetate and povidone (K 
30) in the ratio 8:2 
 
PVA 7200 Polyvinyl alcohol 
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Poly(acrylic acid) Polyacrylic acid 
Luterol® Plyoxyl propylene-polyoxyethylene block 
copolymer 
 
Eudragit RS 100 Ammonio Methacrylate copolymer type B 
Carbopol Acrylic acid and C10-C30 alkyl acrylate 
crosslinked with allyl pentaerythritol 
Soluplus Polyethylene glycol, polyvinyl acetate and 
polyvinylcaprolactame-based graft copolymer 
Chitosan Polysaccharide composed of randomly 
distributed β--linked D-glucosamine and N-
acetyl-D-glucosamine 
 
Preparation of polymeric film forming solutions 
The polymer was dissolved in 95% ethanol kept on stirring overnight until a clear solution 
was obtained. The volume was made up to compensate the solvent lost due to evaporation. 
Subsequently, the formulations were kept in glass vials sealed tightly with Parafilm®. Three 
different concentrations were prepared for each of the screened polymers; 1%, 2.5% and 5% w/w. 
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In vitro evaluation of the polymeric film forming solutions 
The prepared polymeric solutions were initially evaluated according to the following 
characteristics: solution appearance, solution viscosity, film drying time, outward stickiness and 
cosmetic attractiveness of the produced films.  
The appearance of the solutions was evaluated visually and described as clear or opaque 
with or without precipitation of the polymer4. Likewise, the viscosity of the polymeric 
formulations was visually assessed and rated as low (water-like), medium (glycerol-like) or high 
(syrup-like)5. 
For the evaluation of film drying time, the films were formed in small weighing boats. 
After five minutes a glass slide was placed gently on the surface of the film. If no liquid droplets 
are visible on the glass after removing it, the film was considered to be dry. If liquid droplets were 
still visible on the slide, the test was repeated at seven minutes6. 
Additionally, the outward stickiness of the films was estimated by pressing cotton wool on 
the dry film with minimum pressure. Stickiness was rated high if heavy amount of fibers were 
retained on the surface of the film, medium if a thin layer of fibers was formed on the film and low 
if no adherence of fibers was noted5.  
Moreover, the cosmetic appearance of the films was assessed. Complete, uniform and 
transparent films were rated high in cosmetic attractiveness. While incomplete, non-uniform 
and/or visible films were considered to be less attractive. 
Formulations were considered successful when solutions were clear and of low viscosity. 
And when the formed films had a drying time of ≤ 7 minutes, rated low on outward stickiness and 
high in cosmetic attractiveness.  
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Preparation of drug-loaded formulations 
Fourteen FFS formulations passed the in vitro evaluation experiments and were loaded 
with ketoprofen and diclofenac sodium. Table 3 shows the content of such formulations. 
 
 
 
Table 3: Composition of drug loaded FFSs. 
 Drug levels (w/w%) 
Polymer 
(w/w%) 
1 %  1.5% 3% 5% 10% 
Amount of the drug added (mg) 
Kollidon 30 
(2.5%) 
41 62 125.5 213.5 451 
Kollidon 30 
(5%) 
42.5 64 129 220 463 
Kollidon 90F 
(2.5%) 
41 62 125.5 213.5 451 
Kollidon 90F 
(5%) 
42.5 64 129 220 463 
Kollidon SR 
(2.5%) 
41 62 125.5 213.5 451 
Kollidon SR 
(5%) 
42.5 64 129 220 463 
Eudragit 
E100 (2.5%) 
41 62 125.5 213.5 451 
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Eudragit 
E100 (5%) 
42.5 64 129 220 463 
Eudragit 
RLPO 
(2.5%) 
41 62 125.5 213.5 451 
Eudragit 
RLPO (5%) 
42.5 64 129 220 463 
Eudragit 
EPO (2.5%) 
41 62 125.5 213.5 451 
Eudragit 
EPO (5%) 
42.5 64 129 220 463 
Soluplus 
(2.5%) 
41 62 125.5 213.5 451 
Soluplus 
(5%) 
42.5 64 129 220 463 
 
For the preparation of drug loaded FFS formulations, the polymers were first added to 95% 
ethanol kept on stirrer overnight until completely dissolved. To the obtained clear solutions, 
different amounts of ketoprofen and diclofenac sodium were added as shown in table 4. The 
formulations were kept in glass vials sealed tightly with parafilm.  
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Compound light microscopy 
Crystallization of the drugs from the polymeric film forming solutions was evaluated with 
compound light microscopy equipped with 10x, 20x, and 40x objectives. 100 µl of each of the 
formulations was casted on a glass slide and allowed to dry at room temperature. The presence or 
absence of drug’s crystals and their distribution was investigated at four different time points; 15 
minutes, 1 hour, 2 hours and one day. 
Film evaluation on pig skin 
The formulations with the higher drug concentration that didn’t show any signs of drug’s 
crystallization at any time point were considered successful were further assessed using pig skin. 
Fresh porcine skin was brought from a local slaughterhouse. The abdominal skin regions were 
taken and shaved using an electric shaver. The hairless skin was cut into small pieces. The skin 
was mounted on a solid surface and used for film forming solution evaluation. 
 The drying time, outward stickiness and cosmetic attractiveness were evaluated as 
mentioned above. Film flexibility was assessed by stretching the skin in 2-3 directions. The film 
was rated flexible if no signs of cracking or skin fixation were observed or non-flexible if cracking 
or skin fixation occurred1. 
 Formulations that showed short drying time, low outward stickiness, high cosmetical 
attractiveness, and excellent flexibility were considered successful and were evaluated in the in 
vitro drug release study. 
 
In vitro drug release study 
Determination of the transport of the drug across cellulose dialysis membrane was 
performed using vertical Franz diffusion cells. The cells had receiver volume and diffusional 
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surface area of 5 ml and 0.64 cm² respectively. Dialysis membranes were cut into small pieces to 
fit and were mounted on each diffusion cell. The donor and receiver chambers were clamped and 
sealed with Parafilm®. The receiver fluid, Phosphate buffer saline (PBS) pH 7.4 was added and 
any air bubbles trapped next to the membrane were removed initially and after each sampling 
point. Small magnetic stirbars were added to the receiver chamber, and the temperature was 
maintained at 32 °C by a circulating water jacket. To evaluate drug transport, 10 µl/cm² of each 
formulation was added to the donor chamber.  
Table 4 shows the composition of the formulations that were tested at this stage. Samples 
of 200 µl of receiver fluid were removed at 0, 1, 2, 3, 4, 5, 6, 12 and 24 h. Following removal of 
each sample, the same volume of fresh PBS was added to the receiver compartment to maintain 
sink conditions. Samples were analyzed by HPLC. 
Table 4: Composition of FFSs used in the In vitro release study 
Formulation 
Code 
A B C D 
Polymer% 
(w/w) 
Kollidon 30  
5% 
Kollidon 90F  
5% 
Eudragit E100 
5% 
Kollidon 90F 
2.5% 
Drug % w/w Diclofenac Na 
3% 
Diclofenac Na 
3% 
Ketoprofen 
3% 
Ketoprofen  
3% 
95% ethanol 
%w/w 
92% 92% 92% 94.5% 
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Ex vivo permeation study 
Dermatomed human cadaver skin was obtained from New York Firefighters skin Bank 
(525 E. 68th St. New York, NY 100065 USA). The skin was kept at -20 °C and slowly thawed 
before use. The skin was rinsed with water and cut into pieces sufficient enough to cover the 0.64 
cm2 diffusion area of the Franz cells. The skin was then fixed between the absorption and the 
diffusion compartments of the cells, with the epidermis facing the receiver compartment. 10-15 
µl/cm2 of the formulations were applied on the skin. After applying the formulations, 5 ml PBS 
was immediately added to diffusion cells. Incubation temperature was maintained at 32 C, and 
magnetic stirring rate was 600 rpm. Samples were withdrawn at 1, 2, 3, 4, 5, 6, 12 and 24 h, filtered 
and replaced with 5 ml pre-heated fresh PBS at each time point. Drug concentration was 
determined by HPLC. 
Quantification of the drug within skin layers 
Skin samples were removed carefully from the diffusion apparatus, and the exact diffusion 
area was identified and punched out using a biopsy punch. Each skin disc then was rinsed using 
5ml of a rinsing solvent (1ml at a time), and the resulting solutions were collected in glass vials. 
The dried pre-weighted skin discs were immersed in NaOH (1M); the mixture was placed on a 
stirrer for 24h. Subsequently, the extraction mixture was then centrifugated at 1300 rpm for 15min; 
the supernatant fluid was then collected and analyzed by HPLC.  
 
Stability Studies 
Film forming solutions that passed the pig skin testing was kept for stability studies. The 
samples were kept at conditions of 25ᵒC/60% RH and 40ᵒC/75% RH for three months in stability 
chambers. The samples were withdrawn and analyzed for initial and three months. The 
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formulations were evaluated visually for any physical changes in solution appearance and color. 
And drug content in the FFS was analyzed using UV-vis spectrophotometry. Absorbances of 
diclofenac sodium samples were read spectrophotometrically at 275 nm, and for ketoprofen 
samples at 254 nm taking ethanol as blank for both. All measurements were carried out at ambient 
temperature, in a quartz cuvette of 1.00 cm optical length. 
HPLC Analysis 
The samples from in vitro release study and the ex vivo permeation study were analyzed 
for their drug content by HPLC. An isocratic HPLC method was developed for the quantification 
of ketoprofen and diclofenac sodium. The experiment was performed using a Waters HPLC system 
(Water 600 Controller, USA) equipped with a 600-pump unit, a 717 plus autosampler with an 
injection valve with a sample loop of 50 µl, and a 2487 dual absorbance UV detector.   
Diclofenac sodium method: reversed phase Luna® 100° A C18 column (100x4.6 mm, 
3µm, Phenomenex Inc, CA the USA) was utilized at ambient temperature. The mobile phase was 
acetonitrile/water (3:1) adjusted to pH 3 with glacial acetic acid. The flow rate was set at 0.65 
ml/min. Diclofenac sodium was detected at a wavelength of 275 nm with a retention time of 3.5. 
20 µl of the injection was eluted in the column. The calibration curve was prepared using different 
concentrations of diclofenac sodium in the range of 1µg to 10ng using methanol as a solvent. LOD, 
LOQ were determined.  
Ketoprofen method: A method stated in USP-NF was used. Phenomenex Luna® C18 
reverse phase column (100 Å, 250 × 4.6 mm, 5 µm) was used as the solid phase. The mobile phase 
was water, acetonitrile, and glacial acetic acid in the following ratio (90:110:1). The flow rate was 
set at 1.2 mL/min. Ketoprofen was detected at 256 nm (Waters 2489 UV/detector) with a retention 
time of approximately 4.7. Twenty microliters was injected from each sample. A ten point 
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calibration curve was plotted and found to be linear in the concentration range of 2 μg/mL to 100 
μg/mL with a correlation coefficient (R2) of 0.999. The limit of detection and limit of 
quantification values for the method were found to be 0.2 and 0.7 μg/mL, respectively.
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CHAPTER IV 
RESULTS AND DISCUSSION 
Polymer screening and in vitro evaluation of polymeric FSSs 
A selection of 13 polymers from different chemical classes, all described by their 
suppliers or in literature as film formers were evaluated. Each polymer was tested at three 
different concentrations, 1%, 2.5% and 5% w/w.  
The evaluation criteria employed was based on critical features for practical, accurate and 
patient-friendly application of this novel dosage form. The viscosity of the film forming solution 
is required to be low to enable an application of the dosage form as a spray, which would ensure 
accurate and flexible dosing. As a result, only solutions with low viscosity were considered 
successful and were chosen for the next experiment.  
Drying time is a very important characteristic of the formed films. Conveniently, the 
films should have a drying time ≤ 7 minutes so as to avoid long waiting times for the patient.  
Likewise, the prepared films are required to be non-sticky to avoid adhesion to clothes or 
any other surfaces. The cosmetic attribute of films is another essential feature important for 
patients. Patients prefer films that are transparent and flexible
16 
 
 
Table 5 represents the successful formulations that were clear, with low viscosity and 
produced films that were fast drying, with low stickiness and high cosmetic attractiveness. 
Table 5: Composition of the positively evaluated formulations 
 
Polymer 
w/w 
% 
  
Appearance Viscosity Drying 
time 
(min) 
Stickiness Film 
formation 
Cosmetic 
attractiveness 
Kollidon® 
30 
2.5% Clear Low ≤5 Low Complete Transparent 
5% Low 7 
Kollidon® 
90F 
2.5% Clear Low ≤5 Low Complete Transparent 
5% Low 5 
Kollidon® 
SR 
2.5% Clear Low 7 Low Complete Transparent 
5% Low 7 
Eudragit  
RLPO 
2.5% Clear Low ≤5 Low Complete Transparent 
5% Low 7 
Eudragit 
E100   
2.5% Clear Low 5 Low Complete Transparent 
5% Low 5 
Eudragit 
EPO  
2.5% Clear Low 5 Low Complete Transparent 
5% Low 7 
Soluplus 2.5% Clear Low 5 Low Complete Transparent 
 
As can be deducted from the results, both the nature and the content of the polymer have 
a vital impact on the properties of the formed films. The choice of the polymer is important 
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because the polymer has first to be soluble in a volatile skin-tolerant solvent. Polymers that 
aren’t sufficiently soluble in volatile solvents will have the problem of prolonged drying time or 
lacking the ability to give clear solutions and subsequently homogenous clear films. 
Equally important parameter is the polymer content. While increasing the polymer 
amount increases the drug loading capacity of the formulation, this has an inverse impact on the 
viscosity of the formulation as well as the thickness and cosmetic attributes of the produced film. 
More viscous solutions are difficult to dispense and produce films that are thicker, less invisible 
and less flexible. For these reasons the type and the amount of the film forming polymer have to 
be determined carefully when formulating polymeric film-forming solutions.  
Compound light microscopy 
Five different concentrations of each drug in each of the selected polymeric solutions 
were prepared (1%, 1.5%, 3%, 5% and 10% w/w). The results varied with polymer type and 
concentration. Solutions with higher polymer concentrations were able to prevent and stabilize 
the drugs against crystallization. However, the anti-nucleating capacity of the drug was limited 
by the drug solubility in the polymeric matrix. Accordingly, the solutions that passed the 
microscopic evaluation were the ones with the higher polymer concentration and medium drug 
loading capacity. 
Table 6 shows the composition of the formulations that didn’t show any signs of drug 
precipitation and or crystallization at all time points. 
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Table 6:  Composition of drug loaded FFSs that passed the microscopic evaluation. 
Formulation Code Composition 
Formulation A 5% kollidon 30+       3% Diclofenac Na 
Formulation B 5% kollidon 90F+     3% Diclofenac Na 
Formulation C 5% Soluplus    +        3% Diclofenac Na 
Formulation D 2.5% kollidon 90F+   3% ketoprofen 
Formulation E 5% kollidon 90F+       3% ketoprofen 
Formulation F 5% Eudragit E100 +   3% Ketoprofen 
Formulation G 2.5% Eudragit E100+ 3% ketoprofen 
Formulation H 2.5% Eudragit EPO+  3% ketoprofen 
 
Formulation evaluation on pig skin 
After loading the formulations with drugs, it’s crucial at this stage to make sure that the 
drugs’ incorporation hasn’t led to any changes in the desirable film characteristics. Evaluation 
using pig skin provides a better assessment of the films as they are formed on a surface that most 
closely resembles the actual wearing conditions. Consequently, full thickness pig skin was used 
to evaluate the films drying time, stickiness, cosmetic attractiveness and flexibility.  
Film flexibility is a key feature of in situ films produced by FFS. As the solutions are 
expected to be used on considerably large surface areas of the skin, it’s very important for the 
films to be of sufficiently flexible and elastic. This is required to prevent any fissures or cracks 
disrupting the film upon movements of the patient.  
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Table 7 represents the composition of the formulations that gave positive results in all the 
testing criteria. 
Table 7: Composition of FFS that passed the pig skin evaluation experiment. 
Formulation Code Drug (w/w%) Polymer (w/w%) 
A Diclofenac Na (3%) Kollidon 30 (5%) 
B Diclofenac Na (3%) Kollidon 90F (5%) 
C  Ketoprofen (3%) Kollidon 90F (2.5%) 
D Ketoprofen (3%) Eudragit E100 (5%) 
 
In vitro drug release study 
As the principal goal of this work was to formulate FFS capable of producing films that 
prolong topical delivery of NSAIDS. An in vitro experiment method was designed using an 
artificial membrane. The artificial membrane chosen was Cellulose dialysis membrane, which 
has been extensively used to investigate drug release from topical formulations. The membrane-
formulation interactions were assessed in preliminary work, to make sure that the membrane acts 
only as an inert holding not a barrier for drug diffusion once it’s released from the polymeric 
matrix. Data, not showing here, from the 24 h soaking of the membrane in formulations with 
different drug concentrations showed that the membrane didn’t cause any changes in the amount 
of the drug indicating the inertness of the membrane. 
Similarly, solubility testing of the ketoprofen and diclofenac Na in PBS revealed that the 
solubilities of both drugs are at least 20x the expected amounted of the drugs to permeate. The 
solubility of ketoprofen was found to be at least 5 mg/ml and that for diclofenac Na 9 mg/ml. 
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The formulations that adequately satisfied the criteria about drying time, outward 
stickiness, cosmetic acceptability and film flexibility in pig skin testing were evaluated for their 
diffusion ability and release characteristics. 
 Diclofenac release form kollidon 90F and kollidon 30 was investigated. The cumulated 
drug amount released (µg) per unit surface area was plotted as a function of time. Although both 
films sustained diclofenac release for up to 24 h, the release of diclofenac was higher from 
kollidon 90F corresponding to 105 µg/cm² (almost 50% of drug loading) reaching a maximum 
release rate at three h with a steady state release rate reached after 6 h. The differences in the 
release profiles between the two polymers are due to differences in the polymer-drug 
interactions. Such interactions determine the diffusivity of the drug in the polymeric matrix, the 
ability of the polymer to prevent crystallization of the drug and the extent to which the polymer 
is able to support the supersaturated state after solvent evaporation.  
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Figure 1: In vitro release profile of Diclofenac Na from polymeric film-forming 
solutions. (mean of n=3± S.D)  
 
The drug transport data across cellulose dialysis membrane of 3% ketoprofen in kollidon 
90F and 3% ketoprofen in Eudragit are shown in figure 2. As evident from the figure, the release 
of ketoprofen form Eudragit E100 was higher than kollidon 90F. The total amount of ketoprofen 
released was 70 µg/cm² (almost 35% of the loading dose) reaching a maximum release at 2 h 
after which a relatively constant drug release was maintained.  
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Figure 2: In vitro release profile of Ketoprofen from polymeric film-forming 
solutions.  (mean ± standard deviation; n=3) 
 
Based on the presented results 3% Diclofenac in kollidon 90F and 3% Ketoprofen in 
Eudragit E100 were chosen for further optimization and permeation testing using dermatomed 
human cadaver skin. 
Ex vivo permeation study 
To further optimize the performance of the two selected formulations, menthol was added 
at a concentration of 0.08% w/w. Incorporation of penetration enhancer is one of the most common 
methodologies used to improve drug permeation and partitioning into the skin. Key features that 
play an important role when selecting a penetration enhancer are; safety and performance. 
Penetration enhancers shouldn’t cause any irritation or allergizing effect to the skin; also, they 
should have a quick, predictable and reversible effect on the stratum corneum (SC).  
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Menthol a monocyclic terpenoid alcohol has as a long history of use in topical products, 
either for its cooling and refreshing sensation or to enhance the diffusivity and partitioning of both 
hydrophilic and lipophilic drugs 7-10. Menthol acts on the intercellular lipids impeded within the 
stratum corneum corneocyte cells. It exerts its effect via disrupting the highly ordered structure of 
the lipid bilayer, by increasing the fluidity of the SC lipids11. Additionally, menthol is included in 
the list of generally recognized as safe agent list established by the US Food and Drug 
Administration. Therefore, menthol was included in the formulations that gave better results in the 
in vitro release testing. 
Table 8: Final composition of the optimized formulation (w/w%) 
Formulation  Diclofenac in Kollidon 
90F 
Ketoprofen in Eudragit 
E100 
Drug % 3 3 
Menthol % 0.08 0.085 
Polymer % 5 5 
Ethanol %  91.92 91.92 
 
The permeation profile of ketoprofen from Eudragit E100 and 2% ethanolic solution were 
investigated. Statistically, the difference in the steady-state flux of ketoprofen from the test 
formulation and the control is nonsignificant. (p ≥ 0.05). The fact that the test formulation gave 
comparable results to the saturated ethanolic solution indicates that the polymer has a major 
enhancing effect on the drug flux. 
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Figure 3: Ex vivo permeation profile of Ketoprofen from FFS and polymer-free 
saturated ethanolic solution (mean of n=6± S.D) 
 
As for diclofenac sodium permeation study, the results of the permeation study for both 
test formulation and marketed gel Voltaren® didn't result in a good flux profile similar to what 
we saw with ketoprofen. Accordingly, we are only showing the cumulative amount of diclofenac 
sodium retained in the skin. 
Drugs quantification within skin layers 
Figure 4 and 5 show the recovered amount of ketoprofen and diclofenac sodium 
respectively, represented in µg/mg weight of dermatomed skin. In the case of ketoprofen, the 2% 
w/w ethanolic solution of ketoprofen showed a higher amount of retained drug than the 
polymeric FFS, an observation that requires more investigation. 
Even though permeation studies of diclofenac sodium didn’t result in a good flux profile, 
we were able to quantify the amount of drug retained within the skin at the end of the permeation 
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study. Voltaren® gel resulted in a higher amount of the active retained within the skin compared 
to diclofenac sodium FFS.  
 
Figure 4: Recovered amount of ketoprofen in µg/mg of dermatomed skin from 
ketoprofen FFS and a control solution. (mean of n=6 ± SD) 
 
Figure 5: The Recovered amount of diclofenac sodium in µg/mg of dermatomed skin 
from diclofenac sodium FFS and Voltaren® marketed gel. (mean of n=6 ± SD) 
Stability study 
0
1
2
3
4
5
6
7
8
A
m
o
u
n
t 
o
f 
ke
to
p
ro
fe
n
  p
re
se
n
t 
in
 
th
e 
ti
ss
su
e 
(µ
g/
m
g)
3% Ketoprofen in Eudraget E 100          2% Ethanolic solution of ketoprofen 
0
1
2
3
4
5
6
A
m
o
u
n
t 
o
f 
d
ic
lo
fe
n
ac
 N
a 
p
re
se
n
t 
in
 t
h
e 
ti
ss
su
e 
(µ
g/
m
g)
3% Diclofenac in Kollidon 90F         Voltaren gel
26 
 
 
Results from these studies are an essential part of drug development process and mandatory 
requirement by regulatory authorities. Table 10 shows the drug assay results for the four 
formulations that were kept for stability testing at 25°C /40% RH and 40°C /75% RH for 3 months. 
According to the obtained results, all formulations passed stability testing at 3 months, they 
all gave results within the acceptable limits. 
 
 
 
Table 9: 3-month stability testing drug Assay% results (n=3, mean ± SD) 
Formulation Fresh solutions 25°C /40% RH 40°C /75% RH 
3% ketoprofen in 
Eudragit E100 
101.5 ± 0.65 101.16 ± 0.47 101.90 ± 0.18 
3% ketoprofen in 
Kollidon 90F 
102.35 ± 0.34 97.20 ± 0.51 97.37 ± 0.68 
3% diclofenac Na in 
Kollidon 30 
102.21 ± 0.62 97.48 ± 0.60 102.29 ± 0.42 
3% diclofenac Na in 
Kollidon 90F 
103.08 ± 0.05 99.59 ± 0.70 99.20 ± 0.44 
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HPLC Analysis 
Ketoprofen: table 11 shows the HPLC results of ketoprofen standards in methanol. The 
limit of quantification (LOQ) was found to be 0.0625 μg/mL. Lower concentrations than 0.0625 
μg/mL of ketoprofen in methanol were detectable but not quantified precisely. Figure 6 shows 
ketoprofen calibration curve that was found to be linear in the range 0.0625 μg/mL to 100 μg/mL 
with a correlation coefficient (R2 ) of 1.  
 
Table 10: HPLC calculated areas for different ketoprofen standards in methanol 
Concentration 
(µg/ml) 
Area 
100 3281097 
50 1636094 
10 344777 
5 166785 
2.5 83156 
1 32974 
0.5 15877 
0.25 7826 
0.125 4169 
0.0625 1549 
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Figure 6: Ketoprofen standard calibration curve. 
 
Diclofenac sodium: table 12 shows the HPLC results of diclofenac sodium standards in 
methanol. The limit of quantification (LOQ) was found to be 0.125 μg/mL. Lower concentrations 
than 0.125 μg/mL of ketoprofen in methanol were detectable but not quantified precisely. Figure 
7 shows diclofenac sodium calibration curve that was found to be linear in the range 0.125 μg/mL 
to 50 μg/mL with a correlation coefficient (R2 ) of 0.999.  
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Table 11: HPLC calculated areas for different ketoprofen standards in methanol 
Concentration 
(µg/ml) 
Area 
50 810039 
10 162273 
5 79609 
2.5 37629 
1 14757 
0.5 15863 
0.25 3459 
0.125 2977 
 
 
Figure 7: Diclofenac sodium standard calibration curve 
y = 16185x + 472.57
R² = 0.9999
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
0 10 20 30 40 50 60
A
re
a
Concentration (µg/ml) 
 30 
 
 
CHAPTER V 
CONCLUSION 
Film forming solutions were formulated with polymers from different chemical 
groups such as acrylates (Eudragit_ RL PO, Eudragit_ E100, Eudragit_ EPO) Kollidon ( 
30, 90F, SR), Soluplus, Carbopol, and PVA. These formulations contained one of the 
polymers, a volatile solvent, and the drug substance. The developed rating system, even 
though based on qualitative test methods, provided a good basis for the evaluation of the 
developed formulations comprising key features for patients that would ensure higher 
patient satisfaction and compliance. The positively evaluated preparations resulting from 
the formulation experiments provided the basis for the development of film-forming 
polymeric solutions for ketoprofen and diclofenac Na as a novel dosage form for topical 
delivery of non-steroidal anti-inflammatory drugs (NSAIDS).  
The focus of this work was to develop and investigate the release potential of FFS 
of diclofenac Na and ketoprofen. In the case of ketoprofen, Eudragit E100 was identified 
as a potential matrix; producing high-quality films and showing promising release profile 
comparable to a saturated ethanolic solution. For diclofenac Na, due to the poor 
permeability nature of the drug, we didn’t manage to get a flux profile for neither the 
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marketed or our formulation. However, detectable amounts of the drug were found 
retained in the skin after applying the formulations for up to 24 hours.
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